409 related articles for article (PubMed ID: 15124676)
1. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Hochhaus A
Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
[No Abstract] [Full Text] [Related]
2. Imatinib mesylate.
Baker DE
Rev Gastroenterol Disord; 2002; 2(2):75-86. PubMed ID: 12122963
[TBL] [Abstract][Full Text] [Related]
3. Gleevec (STI-571) for chronic myeloid leukemia.
Med Lett Drugs Ther; 2001 Jun; 43(1106):49-50. PubMed ID: 11402258
[No Abstract] [Full Text] [Related]
4. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
de Jong FA; Verweij J
Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
[TBL] [Abstract][Full Text] [Related]
5. Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec).
Joensuu H
Med Klin (Munich); 2002 Jan; 97 Suppl 1():28-30. PubMed ID: 11831069
[TBL] [Abstract][Full Text] [Related]
6. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).
Gordon JK; Magid SK; Maki RG; Fleisher M; Berman E
Leuk Res; 2010 Jun; 34(6):827-9. PubMed ID: 19963273
[TBL] [Abstract][Full Text] [Related]
7. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.
Schoch C; Haferlach T; Kern W; Schnittger S; Berger U; Hehlmann R; Hiddemann W; Hochhaus A
Leukemia; 2003 Feb; 17(2):461-3. PubMed ID: 12592348
[No Abstract] [Full Text] [Related]
8. Imatinib alone and in combination for chronic myeloid leukemia.
Druker BJ
Semin Hematol; 2003 Jan; 40(1):50-8. PubMed ID: 12563611
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate--a new oral targeted therapy.
Savage DG; Antman KH
N Engl J Med; 2002 Feb; 346(9):683-93. PubMed ID: 11870247
[No Abstract] [Full Text] [Related]
10. Cancer treatment in the STI571 era: what will change?
Sawyers CL
J Clin Oncol; 2001 Sep; 19(18 Suppl):13S-16S. PubMed ID: 11560965
[No Abstract] [Full Text] [Related]
11. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
[No Abstract] [Full Text] [Related]
12. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
[TBL] [Abstract][Full Text] [Related]
14. [New oncological treatment principle with imatinib].
Kuenen BC; Pinedo HM
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
[TBL] [Abstract][Full Text] [Related]
15. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
Espinet B; Oliveira AC; Boqué C; Domingo A; Alonso E; Solé F
Haematologica; 2005 Apr; 90(4):556-8. PubMed ID: 15820956
[TBL] [Abstract][Full Text] [Related]
16. [Imatinib and solid tumours].
Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
[TBL] [Abstract][Full Text] [Related]
17. The safety profile of imatinib in CML and GIST: long-term considerations.
Thanopoulou E; Judson I
Arch Toxicol; 2012 Jan; 86(1):1-12. PubMed ID: 21717109
[TBL] [Abstract][Full Text] [Related]
18. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
Garipidou V; Vakalopoulou S; Tziomalos K
Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
[No Abstract] [Full Text] [Related]
19. Clinical pharmacokinetics of imatinib mesylate.
Levêque D; Maloisel F
In Vivo; 2005; 19(1):77-84. PubMed ID: 15796158
[TBL] [Abstract][Full Text] [Related]
20. [Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
Hochhaus A
Dtsch Med Wochenschr; 2002 Mar; 127(9):451-6. PubMed ID: 11870560
[No Abstract] [Full Text] [Related]
[Next] [New Search]
